Loading...
•
Jun 30, 2021
Aurinia Q2 2021 Earnings Report
Reported second quarter financial results with significant revenue increase and patient start forms.
Key Takeaways
Aurinia Pharmaceuticals Inc. reported a net revenue of $6.6 million for the second quarter of 2021, a 624% increase from the first quarter of 2021. The company received 415 patient start forms (PSFs) for LUPKYNISTM during the quarter, representing a 60% increase from the first quarter. The company anticipates that annual net revenue for LUPKYNIS will be in the range of $40 to $50 million for 2021.
Net revenue for the second quarter 2021 was $6.6 million, a 624% increase from the first quarter 2021.
415 patient start forms (PSFs) were received for LUPKYNISTM during the second quarter, over a 60% increase from the first quarter 2021.
Otsuka submitted a voclosporin MAA to the EMA.
Cash and cash equivalents, and investments totaled $323.7 million at June 30, 2021.
Revenue by Segment
Forward Guidance
Aurinia anticipates that annual net revenue for LUPKYNIS will be in the range of $40 to $50 million for 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...